Lonza reports best first half in history with continued strong momentum
Pharma&Biotech’s outstanding operational performance across all assets bolstered the strong half-year results.
In the first half of 2016, Lonza’s Pharma&Biotech and Specialty Ingredients segments both delivered a strong and improved performance and are on track to meet their growth targets for the year. Compared with the same period in 2015, Lonza recorded sales growth of 6.0% to CHF 2,019 million and CORE EBIT growth of 20.0% to CHF 312 million in reported currency. The improvements came from better operational and commercial performance. Net debt was further reduced by CHF 337 million.
“Specifically our Pharma&Biotech segment delivered outstanding operational performance across all of our assets. We are harvesting the fruits of our diligence in implementing productivity programs, as well as the stringent portfolio management activities in Specialty Ingredients and the favorable market environment,” said Richard Ridinger, CEO of Lonza. “These strong half-year results have pushed us to an intermediate sprint towards our ambitious targets and have made us very confident that we will reach our mid-term goals.”
Pharma&Biotech substantially increased sales and CORE results compared with the same period last year. The great performance throughout the first half was mainly driven by the excellent operational performance of the segment, a strong momentum in the mammalian business, a generally solid market demand and ongoing cost discipline. Also the made-to-stock Bioscience Solutions business delivered strong growth in both sales and profits.
All biological technologies experienced positive growth momentum. The outsourcing trend is persisting, as evidenced by the fact that in 2016 Pharma&Biotech will provide drug substances for 20 commercial biologics. This outsourcing trend should continue to increase in the future.
As part of the growth strategy, Lonza complemented its primary-cell offering with the acquisition of Triangle Research Labs, a hepatocyte provider based in North Carolina (USA) during the first half of 2016.
Emerging Technologies also experienced strong growth momentum and took a leading role in setting a platform to bring new technologies to commercial scale during the first half of the year. One example is the long-term commercial partnership with bluebird bio, Inc., a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer.
With this positive first half of 2016 and the good momentum expected to continue into the second half of the year, Lonza is raising its guidance for CORE EBIT growth and now expects a double-digit improvement in CORE EBIT for the full year of 2016.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance